tiprankstipranks
Advertisement
Advertisement

BOVNF Stock Latest News

BioInvent Narrows Pipeline and Advances Lead Cancer Antibodies in Strategically Focused 2025
Company AnnouncementsBioInvent Narrows Pipeline and Advances Lead Cancer Antibodies in Strategically Focused 2025
13d ago
BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3
PremiumCompany Announcements
BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3
18d ago
BioInvent Calls 2026 AGM, Sets Governance and Voting Framework
PremiumCompany Announcements
BioInvent Calls 2026 AGM, Sets Governance and Voting Framework
20d ago
BioInvent Earnings Call: Strong Data, Tight Runway
PremiumCompany Announcements
BioInvent Earnings Call: Strong Data, Tight Runway
1M ago
BioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
PremiumCompany Announcements
BioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
2M ago
BioInvent to Present 2025 Year-End Results in Investor Webcast
PremiumCompany AnnouncementsBioInvent to Present 2025 Year-End Results in Investor Webcast
2M ago
BioInvent Taps Industry Heavyweights for Board as Cancer Pipeline Advances
Premium
Company Announcements
BioInvent Taps Industry Heavyweights for Board as Cancer Pipeline Advances
2M ago
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
Premium
Company Announcements
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
3M ago
BioInvent Steps Up Investor Outreach with Series of 2026 Healthcare Conferences
PremiumCompany Announcements
BioInvent Steps Up Investor Outreach with Series of 2026 Healthcare Conferences
4M ago
BioInvent’s BT-001 Clinical Trial Termination: Implications for Investors
PremiumCompany Announcements
BioInvent’s BT-001 Clinical Trial Termination: Implications for Investors
4M ago
BOVNF
BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
PremiumCompany Announcements
BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
4M ago
BioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
PremiumCompany Announcements
BioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
4M ago
BioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment
PremiumCompany AnnouncementsBioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment
5M ago
BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation
Premium
Company Announcements
BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation
5M ago
BioInvent’s BI-1910 Shows Promise in Phase 1 Trials for Solid Tumors
Premium
Company Announcements
BioInvent’s BI-1910 Shows Promise in Phase 1 Trials for Solid Tumors
5M ago
BioInvent to Present Promising Phase 2a Data at ASH 2025
PremiumCompany Announcements
BioInvent to Present Promising Phase 2a Data at ASH 2025
5M ago
BioInvent to Present Promising BI-1808 Data at ASH 2025
PremiumCompany Announcements
BioInvent to Present Promising BI-1808 Data at ASH 2025
5M ago
BioInvent’s Earnings Call: Strategic Gains Amid Financial Challenges
PremiumCompany Announcements
BioInvent’s Earnings Call: Strategic Gains Amid Financial Challenges
5M ago
BioInvent’s Strategic Focus on Lead Cancer Therapies
PremiumCompany Announcements
BioInvent’s Strategic Focus on Lead Cancer Therapies
6M ago
BioInvent Prioritizes Advanced Programs to Boost Cancer Therapy Development
PremiumCompany AnnouncementsBioInvent Prioritizes Advanced Programs to Boost Cancer Therapy Development
6M ago
BioInvent to Present Interim Report for January-September 2025
Premium
Company Announcements
BioInvent to Present Interim Report for January-September 2025
6M ago
BioInvent and Transgene’s BT-001 Shows Promising Results in Cancer Treatment
Premium
Company Announcements
BioInvent and Transgene’s BT-001 Shows Promising Results in Cancer Treatment
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >